Phenotype and clinical outcomes of titin cardiomyopathy
File(s)2264.full.pdf (1022.78 KB)
Published version
Author(s)
Type
Journal Article
Abstract
Background Improved understanding of dilated cardiomyopathy (DCM) due to titin truncation (TTNtv) may help guide patient stratification.
Objectives The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM.
Methods In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events.
Results Of 716 subjects recruited (mean age 53.5 ± 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m2 reduction; padjusted = 0.03) compared with patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtv+/− groups. Overall, 78 of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years), including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted for primary endpoint: 0.92 [95% confidence interval: 0.45 to 1.87]; p = 0.82).
Conclusions In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be associated with worse medium-term prognosis.
Objectives The purpose of this study was to establish relationships among TTNtv genotype, cardiac phenotype, and outcomes in DCM.
Methods In this prospective, observational cohort study, DCM patients underwent clinical evaluation, late gadolinium enhancement cardiovascular magnetic resonance, TTN sequencing, and adjudicated follow-up blinded to genotype for the primary composite endpoint of cardiovascular death, and major arrhythmic and major heart failure events.
Results Of 716 subjects recruited (mean age 53.5 ± 14.3 years; 469 men [65.5%]; 577 [80.6%] New York Heart Association function class I/II), 83 (11.6%) had TTNtv. Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and had lower indexed left ventricular mass (5.1 g/m2 reduction; padjusted = 0.03) compared with patients without TTNtv. There was no difference in biventricular ejection fraction between TTNtv+/− groups. Overall, 78 of 604 patients (12.9%) met the primary endpoint (median follow-up 3.9 years; interquartile range: 2.0 to 5.8 years), including 9 of 71 patients with TTNtv (12.7%) and 69 of 533 (12.9%) without. There was no difference in the composite primary outcome of cardiovascular death, heart failure, or arrhythmic events, for patients with or without TTNtv (hazard ratio adjusted for primary endpoint: 0.92 [95% confidence interval: 0.45 to 1.87]; p = 0.82).
Conclusions In this large, prospective, genotype-phenotype study of ambulatory DCM patients, we show that prognostic factors for all-cause DCM also predict outcome in TTNtv DCM, and that TTNtv DCM does not appear to be associated with worse medium-term prognosis.
Date Issued
2017-10-31
Date Acceptance
2017-08-30
Citation
Journal of the American College of Cardiology, 2017, 70 (18), pp.2264-2274
ISSN
0735-1097
Publisher
Elsevier
Start Page
2264
End Page
2274
Journal / Book Title
Journal of the American College of Cardiology
Volume
70
Issue
18
Copyright Statement
© 2017 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN
COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER
THE CC BY LICENSE ( http://creativecommons.org/licenses/by/4.0/ ) .
COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER
THE CC BY LICENSE ( http://creativecommons.org/licenses/by/4.0/ ) .
License URL
Sponsor
Medical Research Council
British Heart Foundation
Wellcome Trust
Royal Brompton & Harefield NHS Foundation Trust
Wellcome Trust
Department of Health
British Heart Foundation
Fondation Leducq
Fondation Leducq
Royal Brompton & Harefield NHS Foundation Trust
Royal Brompton & Harefield NHS Foundation Trust
British Heart Foundation
Medical Research Council (MRC)
British Heart Foundation
British Heart Foundation
Grant Number
MR/M003191/1
FS/13/13/29819
107469/Z/15/Z
N/A
100134/Z/12/Z
HICF-R6-373
SP/10/10/28431
11 CVD-01
11 CVD-01
6178/39020
RBHT6179
FS/17/21/32712
MR/M003191/1
FS/15/29/31492
FS/17/21/32712
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
DCM
genetics
CMR
titin
SUDDEN CARDIAC DEATH
DILATED CARDIOMYOPATHY
HEART-FAILURE
ASSOCIATION
ARRHYTHMIAS
MILD
CMR
DCM
genetics
titin
Adolescent
Adult
Aged
Aged, 80 and over
Cardiomyopathy, Dilated
Child
Cohort Studies
Connectin
Female
Follow-Up Studies
Humans
Male
Middle Aged
Phenotype
Prospective Studies
Single-Blind Method
Treatment Outcome
Young Adult
Humans
Cardiomyopathy, Dilated
Treatment Outcome
Cohort Studies
Follow-Up Studies
Prospective Studies
Single-Blind Method
Phenotype
Adolescent
Adult
Aged
Aged, 80 and over
Middle Aged
Child
Female
Male
Young Adult
Connectin
Cardiovascular System & Hematology
1102 Cardiorespiratory Medicine and Haematology
1117 Public Health and Health Services
Publication Status
Published
Date Publish Online
2017-10-23